Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2026)

Acadia Pharmaceuticals' Tax Provisions history runs 10 years deep, the most recent figure standing at $300000.0 for Q1 2026.

• On a quarterly basis, Tax Provisions fell 96.59% year-over-year to $300000.0 in Q1 2026; TTM through Mar 2026 was -$33.4 million, a 424.3% decrease from a year earlier, with the FY2025 full-year figure at -$24.8 million, down 516.43% from the prior year.
• Tax Provisions rose to $300000.0 in Q1 2026 per ACAD's latest filing, from -$20.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $13.5 million in Q2 2025 and bottomed at -$27.2 million in Q3 2025.
• The 5-year median for Tax Provisions is $768000.0 (2022), against an average of -$346882.4.
• Across the five-year window, Tax Provisions soared 2209.52% in 2022 and tumbled 856.25% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $800000.0 in 2022, then tumbled by 856.25% to -$6.0 million in 2023, then tumbled by 37.85% to -$8.3 million in 2024, then sank by 140.04% to -$20.0 million in 2025, then soared by 101.5% to $300000.0 in 2026.
• Per Business Quant, the three latest ACAD Tax Provisions figures stand at $300000.0 (Q1 2026), -$20.0 million (Q4 2025), and -$27.2 million (Q3 2025).